Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05064358
Title Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14)
Acronym DREAMM 14
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUS | ARG


No variant requirements are available.